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Comparative Effects of
Prolonged and Intermittent
Stimulation of the Glucagon-
Like Peptide 1 Receptor on
Gastric Emptying and Glycemia
Acute administration of glucagon-like peptide 1
(GLP-1) and its agonists slows gastric emptying,
which represents the major mechanism underlying
their attenuation of postprandial glycemic
excursions. However, this effect may diminish
during prolonged use. We compared the effects
of prolonged and intermittent stimulation of the
GLP-1 receptor on gastric emptying and glycemia.
Ten healthy men received intravenous saline
(placebo) or GLP-1 (0.8 pmol/kg $ min), as
a continuous 24-h infusion (“prolonged”), two
4.5-h infusions separated by 20 h (“intermittent”),
and a 4.5-h infusion (“acute”) in a randomized,
double-blind, crossover fashion. Gastric emptying
of a radiolabeled mashed potato meal was
measured using scintigraphy. Acute GLP-1
markedly slowed gastric emptying. The magnitude
of the slowing was attenuated with prolonged but
maintained with intermittent infusions. GLP-1
potently diminished postprandial glycemia during
acute and intermittent regimens. These
observations suggest that short-acting GLP-1
agonists may be superior to long-acting agonists
when aiming speciﬁcally to reduce postprandial
glycemic excursions in the treatment of type 2
diabetes.
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Acute administration of glucagon-like peptide 1 (GLP-
1) to healthy humans, and patients with type 2 di-
abetes, lowers blood glucose concentrations by stimu-
lating insulin, suppressing glucagon secretion, and
slowing gastric emptying (1). GLP-1 agonists have been
incorporated into standard algorithms to treat hyper-
glycemia in patients with type 2 diabetes, and while
the objective of these treatment regimens is to reduce
glycemia safely (2), the importance of speciﬁcally tar-
geting postprandial glycemia is increasingly being
recognized (3). The capacity for GLP-1, and its ago-
nists, to slow gastric emptying represents the domi-
nant mechanism by which they reduce postprandial
glycemic excursions (4,5).
Long-acting GLP-1 agonists are attractive, since fewer
injections are required (6,7). However, there is pre-
liminary evidence that the slowing of gastric emptying by
long-acting agonists becomes attenuated over time
(6,8–10), although only one study has hitherto examined
directly whether sustained GLP-1 receptor activation
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induces tachyphylaxis for the effects of GLP-1 on gastric
emptying (11). In this study, the delay in gastric emp-
tying of a liquid meal was reported to be diminished
after administration of intravenous GLP-1 for 270 min
compared with 30 min (11), but methodological limi-
tations included the use of a suboptimal dye dilution
technique to quantify gastric emptying and the provision
of a second meal only 4 h after the ﬁrst, with potential for
incomplete emptying of the ﬁrst meal or ongoing
nutrient stimulation of the small intestine to inﬂuence
the disposition of the second meal. Furthermore, this
previous study did not evaluate the effect of intermittent
GLP-1 receptor stimulation, which is of substantial clinical
relevance.
We undertook the current study to determine ac-
curately whether tachyphylaxis to the effect of GLP-1
on gastric emptying occurs rapidly and affects post-
prandial glycemia. The primary hypothesis was that
intermittent administration of GLP-1 would slow
gastric emptying more than prolonged continuous
administration. Secondary hypotheses were that 1)
prolonged infusion of GLP-1 would still slow gastric
emptying compared with placebo, 2) the effects of in-
termittent and acute GLP-1 infusions on gastric emp-
tying would be similar, and 3) postprandial glycemic
excursions would be related to the rate of gastric
emptying.
RESEARCH DESIGN AND METHODS
Healthy men aged 18–35 years were eligible, and those
with diabetes (HbA1c .6.0% or 42.1 mmol/mol), im-
paired renal function or anemia, currently smoking,
consuming .20 g/day alcohol, receiving medication
known to affect gastrointestinal motility or glycemia,
or with a history of gastric or small intestinal surgery
were excluded.
Each subject attended the hospital after an overnight
fast on two occasions separated by at least 4 days to be
studied under regimens A and B in a randomized, double-
blind fashion. Randomization was carried out by the
Royal Adelaide Hospital Pharmacy using a Web-based
program. Allocation concealment was maintained
throughout. An intravenous catheter was inserted into
each arm for drug delivery and blood sampling. Gastric
emptying was measured at approximately the same time
of day in each subject. During study visits, energy intake
was standardized and subjects remained sitting or lying,
unless toileting. GLP-1 (7–36)amide (Bachem, Germany)
was infused at a rate of 0.8 pmol/kg/min, which is known
to result in receptor stimulation representative of phar-
macological agents (11). Placebo was 0.9% sodium chlo-
ride, and all study drugs were infused at 1 mL/min.
Regimen A
Subjects received an intravenous infusion of GLP-1 for
4.5 h followed by 19.5 h of placebo and, ﬁnally, 4.5 h of
GLP-1. The response to “intermittent” GLP-1 was
assessed during the second GLP-1 infusion (Fig. 1).
Regimen B
Subjects received a 4.5-h intravenous infusion of placebo
followed by 24 h of GLP-1. The effect of “prolonged”
GLP-1 exposure was assessed after 20 h of GLP-1 in-
fusion (Fig. 1). The study protocol was approved by the
Royal Adelaide Hospital Research Ethics Committee and
registered as a clinical trial. Written informed consent
was obtained from the subjects.
Gastric Emptying
Radioisotopic data were acquired with the subjects seated
with their back against a g camera (GE Healthcare). On
four occasions (Fig. 1), subjects ingested a test meal
comprising 65 g powdered mashed potato (Deb Instant;
Continental, Sydney, Australia), 45 g margarine (Flora
Figure 1—Study protocol. Scintigraphic measurements of gastric emptying were performed over 4 h both from T = 0 h to T = 4 h and
T = 24 h to T = 28 h. Infusion of study drug was commenced 30 min prior to ingestion of meal to allow for plasma concentrations to
reach steady-state.
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Original; Unilever, Sydney, Australia), 20 g glucose, and
200 mL water, labeled with 20 MBq 99mTc-calcium-
phytate colloid. The meal contained 2,687 kJ (642 kcal),
with 72.3 g carbohydrate, 35.5 g fat, and 8.1 g protein.
Scintigraphic images were acquired every minute for the
ﬁrst hour and then at 3-min intervals for a further 3 h.
A left lateral image of the stomach was acquired to
correct for g-ray attenuation (12). Data were also cor-
rected for radioactive decay and subject movement. A
region of interest was drawn around the total stomach,
and percent retention was determined at 0, 30, 60, 90,
120, 150, 210, and 240 min. The time taken for the
stomach to empty 50% (T50) was also calculated (12).
Blood Glucose and Insulin
Blood glucose concentrations were measured using
a blood gas analyzer (ABL800 Flex; Radiometer Medical,
Brønshøj, Denmark), and serum insulin was measured by
ELISA (Mercodia) (13). Blood was sampled at 230, 0, 30,
60, 90, 120, and 180 min.
Statistical Analysis
Data are presented as mean (95% CI). Area under the
blood glucose curve (AUC) was derived using the trape-
zoidal rule. The sample size was calculated using SD of
25% around the mean gastric emptying of a similar meal
(14), with an anticipated reduction in gastric slowing
during prolonged GLP-1 administration of 50% (11).
Allowing for 10% greater margins, at least nine subjects
were required (b = 0.8, a = 0.05); therefore, we studied
10 subjects.
A mixed-effects maximum likelihood model, with in-
fusion as a ﬁxed effect, was used to determine differences
between infusions. If an effect was present, post hoc
pairwise analysis was conducted between infusions, with
Bonferonni corrections for repeated testing. P values
,0.05 were considered signiﬁcant.
Because after a similar meal we have previously
reported 1) strong associations between glycemic excur-
sions during the initial 60 min and the rate of gastric
emptying (14) and 2) serum insulin concentrations
markedly elevated for 180 min, glycemia was calculated
as AUC60 and insulinemia as AUC180. The relationships
between gastric emptying, glycemia, and insulinemia
were determined using univariate analysis, with correc-
tion for within-subject correlations (15).
RESULTS
Ten healthy male subjects (age 24 [95% CI 23–25] years,
BMI 25 [22–27] kg/m2) completed the study without any
adverse effects.
Gastric Emptying
All GLP-1 infusions slowed gastric emptying compared
with placebo (P , 0.001) (Fig. 2). Acute GLP-1 compared
with placebo increased intragastric retention (P = 0.001),
as did intermittent compared with prolonged infusion
(P = 0.04) (Fig. 2). While prolonged infusion increased
retention in comparison with placebo (P = 0.003), acute
and intermittent infusions had similar effects (P = 1.0)
(Fig. 2). T50 was affected by the study infusion (P =
0.01), with acute infusion (143 min [104–183] min)
delaying the T50 compared with placebo (79 min [65–
94]); P = 0.02) and a trend for intermittent (168 min
[109–225]) to delay compared with prolonged (122 min
[75–170]; P = 0.09). However, there was no signiﬁcant
difference in T50 between prolonged and placebo (P =
0.26) or acute and intermittent (P = 0.69) infusions.
Blood Glucose and Serum Insulin
There was a small, but statistically signiﬁcant, differ-
ence in fasting blood glucose concentrations prior to
saline or GLP-1 infusions (T = 230: placebo 5.5 mmol/L
[5.2–5.7] vs. acute 5.0 mmol/L [4.7–5.3]; P , 0.001).
Postprandial glycemia (AUC60) was affected by the in-
fusion (P , 0.001) (Supplementary Fig. 1). Acute GLP-1
reduced postprandial glycemia (AUC60) compared with
placebo (P = 0.001), as did intermittent compared with
prolonged (P = 0.007), but there was no difference be-
tween prolonged and placebo (P = 0.21) or acute and
intermittent (P = 1.0) regimens (Fig. 3A). The peak blood
glucose concentration was affected by the infusion (P ,
0.001), being greater during placebo 7.1 mmol/L (6.4–
7.7) than either acute (5.8 mmol/L [5.4–6.3]), in-
termittent (6.0 mmol/L [5.5–6.4]), or prolonged (6.6
mmol/L [6.1–7.2]) GLP-1 infusions.
Fasting insulin concentrations were similar [T = 230:
placebo (5 mU/L [4–6]) vs. acute (5 mU/L [3–6]; P =
0.15)]. Overall insulin secretion was affected by the study
infusion (P , 0.001) (Supplementary Fig. 2). Postprandial
insulin concentrations were reduced during intermittent
Figure 2—The effect of different GLP-1 regimens on gastric
emptying. There was an effect between the various infusions
(P < 0.001). Acute GLP-1 compared with placebo increased
intragastric retention (P = 0.001), as did intermittent compared
with prolonged infusion (P = 0.04). While prolonged infusion
increased retention in comparison with placebo (P = 0.003),
acute and intermittent infusions had similar effects (P = 1.0).
Data are mean 6 SEM. A mixed-effects maximum likelihood
model was used to determine differences with post hoc testing
adjusted for multiple comparisons.
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compared with prolonged infusion (P = 0.003), but there
was no statistically signiﬁcant difference between acute
GLP-1 and placebo (P = 0.07) (Fig. 3B). Postprandial in-
sulin concentrations were comparable between acute and
intermittent infusions (P = 1.0) and between prolonged
infusion and placebo (P = 0.85) (Fig. 3B).
Peak insulin concentrations were also affected (P =
0.003), with secretion less during acute (25.1 mU/L
[16.4–33.8]) than placebo (39.8 mU/L [31.9–47.6]), P =
0.03, and less during intermittent (21.0 mU/L [14.6–
27.4 when compared with prolonged (43.0 mU/L [28.0–
58.0]), P = 0.03. However, peak insulin concentrations
were similar between prolonged and placebo and between
acute and intermittent (P = 1.0 for both). The insulin-to-
glucose ratios (AUC180) were similarly affected. Due to
slower emptying, the ratios were less with acute than
placebo (P = 0.035) and intermittent compared with
prolonged (P = 0.002) (Supplementary Fig. 3).
Relationship Between Gastric Emptying, Postprandial
Glycemia, and Insulinemia
There were strong associations between gastric emptying
and postprandial glycemia (AUC60: r = 20.49; P = 0.005)
(Fig. 4A) and between gastric emptying and insulinemia
(AUC240: r = 20.41; P = 0.02 [Fig. 4B] and % gastric
retention AUC60 vs. insulin peak: r = 20.46; P = 0.01), so
that when gastric emptying was faster, glycemic and in-
sulin excursions were greater.
DISCUSSION
This study establishes that while acute, intermittent, and
prolonged infusions of exogenous GLP-1 all slow gastric
emptying substantially in health, the magnitude of this
effect is attenuated during prolonged stimulation, which
reduces the effect of GLP-1 on postprandial glycemic
excursions.
Figure 3—The effect of different GLP-1 regimens on postprandial
glycemia and insulinemia. A: There was an effect between infu-
sions (P < 0.001). Acute GLP-1 reduced postprandial glycemia
(AUC0–60) compared with placebo (*P = 0.001), as did intermittent
compared with prolonged (#P = 0.007), but there was no difference
between prolonged and placebo (P = 0.21) or acute and in-
termittent (P = 1.0) regimens. B: There was an effect between the
various infusions (P < 0.001). Postprandial insulin concentrations
were reduced during intermittent compared with prolonged in-
fusion (*P = 0.003); comparing acute infusion with placebo, the
difference was not statistically signiﬁcant (P = 0.07). Postprandial
insulin concentrations were comparable between acute and in-
termittent infusions (P = 1.0) and between prolonged infusion and
placebo (P = 0.21). Data are mean 6 SEM. A mixed-effects
maximum likelihood model was used to determine differences with
post hoc testing adjusted for multiple comparisons. IV, intravenous.
Figure 4—Correlation between gastric emptying, glycemia, and
insulinemia. The rate of gastric emptying (% gastric retention
AUC60) was closely associated with postprandial glycemia (AUC60:
r = 20.49; P = 0.005) (A) and postprandial insulinemia (AUC180: r =
20.41; P = 0.02) (B). Data are correlated within subject (15).
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These observations were anticipated and are consis-
tent with the notion that short-acting agonists appear to
have a substantial, and sustained, effect to slow gastric
emptying, whereas the acute effects of long-acting ago-
nists on gastric emptying diminish with ongoing use
(6,9,10,16). Indeed, while prolonged stimulation with
exenatide once a week lowers postprandial glycemia, the
magnitude of lowering is greater when exenatide twice
daily is administered (6).
While a similar effect on gastric emptying was sug-
gested by both Nauck et al. (11) and Näslund et al. (8)
there were limitations with both studies. In both studies,
the methods used to measuring measure gastric empty-
ing were less than optimal and, in the former study, were
also confounded by potential order effects, while in the
latter study intermittent stimulation was achieved using
suprapharmacological bolus dosing. However, building on
these previous observations (8,11), our data establish
unequivocally that tachyphylaxis to the gastric motor
effects of GLP-1 occurs. Moreover, our study design
allowed us not only to compare the effects of continuous
and intermittent GLP-1 receptor stimulation at plasma
concentrations that are similar to plasma concentrations
achieved during standard dosing with commercially
available short and long-acting GLP-1 agonists
(6,11,16,17) but also to evaluate its impact on post-
prandial glycemia, which indicates that this phenomenon
is clinically relevant.
It should be recognized that with prolonged (~24 h)
GLP-1 receptor stimulation, the slowing of gastric emp-
tying compared with placebo was attenuated but not
abolished. This is important given that even modest
changes in gastric emptying have the potential to affect
postprandial glycemia substantially in patients with di-
abetes (18). It remains to be determined whether effects
on gastric emptying would be further attenuated with
receptor stimulation beyond 24 h.
It remains uncertain why there is tachyphylaxis to the
effect of GLP-1 to slow gastric emptying and not to the
islet cell effects, but there is limited evidence to suggest
a role for vagal pathways (11). It should be recognized
that the test meal had a substantial carbohydrate and
calorie content and that potentially the magnitude of
attenuation of the slowing of gastric emptying by exog-
enous GLP-1 may be inﬂuenced by meal composition
(14,19). Other potential limitations are that we chose to
study healthy volunteers in order to minimize potential
confounding by marked hyperglycemia (which is itself
known to slow gastric emptying) (20), autonomic neu-
ropathy (which may inﬂuence the effects of GLP-1 on the
proximal stomach) (21), and the potential for abnormally
slow gastric emptying at baseline (22,23). The latter
variable may be particularly important, as the capacity
for GLP-1 to slow gastric emptying is dependent on the
underlying rate of emptying (5). Aside from these fac-
tors, it is anticipated that patients with type 2 diabetes
would respond similarly to healthy subjects, but this is
not assured (2,6,7,24).
The clinical relevance of our study will require con-
ﬁrmatory studies comparing GLP-1 agonists in type 2
patients that have problematic postprandial glycemic
excursions, particularly in those with normal, or rapid,
gastric emptying. While long-acting agonists may have
greater potency to reduce HbA1c in unselected patients
with type 2 diabetes (6,25), the use of an isotope breath
test to measure gastric emptying has the potential to
determine whether short-acting agonists may be more
appropriate for a particular patient (16). Such an ap-
proach would, however, need to evaluate postprandial
effects against any potential worsening of preprandial
glycemia (26).
In conclusion, there is a marked attenuation of the
magnitude of slowing of gastric emptying with prolonged
compared with intermittent stimulation of the GLP-1
receptor in health, supporting the concept of rapid
tachyphylaxis. Moreover, the reduction in postprandial
glycemia induced by GLP-1 is dependent on the magni-
tude of slowing of emptying. These data suggest that the
choice of GLP-1 agonist for a given patient should be
based on the relative importance of targeting post-
prandial glycemia for an individual patient.
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